Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
January 14, 2025

MIREVO®, the first neuropsychological testing program in Japan to support dementia treatment, now available

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ai-BrainScience Inc. announce that MIREVO®, a program for neuropsychological testing to support medical treatment of dementia, has become the first Software as a Medical Device (SaMD) in the field of of dementia to obtain national health insurance coverage as of January 1, 2025. Marketing of the product in Japan began today.

With the desire for early detection of dementia, testing methods using new technologies are being developed. MIREVO is a neuropsychological testing program that uses eye tracking technology. The test can be easily conducted and results can be obtained in approximately three minutes using the MIREVO app on a tablet. By having the test subject focus on the correct areas in response to the questions displayed on the screen, data is automatically scored. This allows for a quantitative and objective evaluation, which is not dependent on the examiner's knowledge or experience.

In a clinical study conducted on subjects with diagnosed dementia and other subjects (including cognitively normal subjects and subjects with suspected mild cognitive impairment), MIREVO showed a correlation between test scores from this program and the overall Mini Mental State Examination (MMSE) as the primary endpoint. The secondary endpoint was a reduction in examiner burden compared to the MMSE, and here a reduction in examiner burden was confirmed in comparison with the MMSE.

MIREVO is expected to expand the options for neuropsychological testing and help in the early detection of dementia through use of eye tracking technology.

By developing diagnostic businesses in addition to its pharmaceutical business, Otsuka continues efforts to provide comprehensive options in the treatment of dementia and aims to become a total healthcare company addressing challenges society faces as a whole.